Sitravatinib sensitizes ABCB1-and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs
CP Wu, SH Hsiao, YH Huang, LC Hung, YJ Yu… - Cancers, 2020 - mdpi.com
The development of multidrug resistance (MDR) in cancer patients driven by the
overexpression of ATP-binding cassette (ABC) transporter ABCB1 or ABCG2 in cancer cells …
overexpression of ATP-binding cassette (ABC) transporter ABCB1 or ABCG2 in cancer cells …
The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs
CP Wu, TH Hung, S Lusvarghi, YH Chu… - Biochemical …, 2021 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) drug transporter ABCB1 (P-
glycoprotein, P-gp) or ABCG2 (breast cancer resistance protein, BCRP) in cancer cells often …
glycoprotein, P-gp) or ABCG2 (breast cancer resistance protein, BCRP) in cancer cells often …
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of …
C Hegedüs, K Truta-Feles, G Antalffy, G Várady… - Biochemical …, 2012 - Elsevier
Human ABCG2 is a plasma membrane glycoprotein that provides physiological protection
against xenobiotics. ABCG2 also significantly influences biodistribution of drugs through …
against xenobiotics. ABCG2 also significantly influences biodistribution of drugs through …
Targeting ABCB1 and ABCC1 with their specific inhibitor CBT-1® can overcome drug resistance in osteosarcoma
M Fanelli, C Maria Hattinger, S Vella… - Current cancer drug …, 2016 - ingentaconnect.com
Clinical treatment response achievable with conventional chemotherapy in high-grade
osteosarcoma (OS) is severely limited by the presence of intrinsic or acquired drug …
osteosarcoma (OS) is severely limited by the presence of intrinsic or acquired drug …
ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors
J Deng, J Shao, JS Markowitz, G An - Pharmaceutical research, 2014 - Springer
The past decade has seen tremendous efforts in the research and development of new
chemotherapeutic drugs using target-based approaches. These efforts have led to the …
chemotherapeutic drugs using target-based approaches. These efforts have led to the …
[HTML][HTML] Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo
X Wang, KKW To, L Huang, J Xu, K Yang, F Wang… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Multidrug resistance (MDR) to chemotherapeutic drugs is a formidable barrier to the success
of cancer chemotherapy. Expressions of ATP-binding cassette (ABC) transporters contribute …
of cancer chemotherapy. Expressions of ATP-binding cassette (ABC) transporters contribute …
Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells
G Chakravarty, A Mathur, P Mallade, S Gerlach, J Willis… - Biochimie, 2016 - Elsevier
Abstract Development of multidrug resistance (MDR) remains a significant problem in
cancer chemotherapy and underscores the importance of using chemosensitizers. Well …
cancer chemotherapy and underscores the importance of using chemosensitizers. Well …
Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in vitro
SH Hsiao, YJ Lu, YQ Li, YH Huang… - Molecular …, 2016 - ACS Publications
The effectiveness of cancer chemotherapy is often circumvented by multidrug resistance
(MDR) caused by the overexpression of ATP-binding cassette (ABC) drug transporter …
(MDR) caused by the overexpression of ATP-binding cassette (ABC) drug transporter …
Drug resistance-related competing interactions of lncRNA and mRNA across 19 cancer types
Drug resistance is a common cause of treatment failure in cancer therapy, and molecular
mechanisms need further exploration. Competing endogenous RNAs (ceRNAs) can …
mechanisms need further exploration. Competing endogenous RNAs (ceRNAs) can …
[HTML][HTML] P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors
J Kopecka, GM Rankin, IC Salaroglio, SA Poulsen… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Carbonic anhydrase XII (CAXII) is a membrane enzyme that maintains pH homeostasis and
sustains optimum P-glycoprotein (Pgp) efflux activity in cancer cells. Here, we investigated a …
sustains optimum P-glycoprotein (Pgp) efflux activity in cancer cells. Here, we investigated a …